Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir to prevent severe COVID-19 after kidney transplantation in SARS-CoV-2-positive recipients
2024-519272-96-00Phase 2Authorised
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Development of severe COVID-19 after transplantation. Planned start Aug 2025; status: authorised.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-519272-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519272-96-00.